Why Some Cancers Need Less Treatment Before They Need More

The Strange Case for Doing Less First

What if the most sophisticated cancer strategy is not to start by adding more treatment, but by resisting the urge to intervene too early? That question sits at the center of two very different clinical worlds: one in which advanced prostate cancer is increasingly sorted by molecular subtype to decide whether a patient should receive chemotherapy or androgen receptor targeting, and another in which localized kidney cancer is being explored as a candidate for preoperative systemic therapy even though that approach is not yet standard.

At first glance, these are separate stories. One is about choosing among therapies in metastatic hormone sensitive prostate cancer. The other is about using drugs before surgery in localized renal cell carcinoma. But together they point to a deeper shift in oncology: the old model of treatment as a uniform, sequential weapon is giving way to a more nuanced model in which timing, biology, and tumor context matter as much as the drug itself.

The real question is not simply, “Which treatment works?” It is, “For which biology, at which moment, and with what downstream consequences?”

That question changes everything.

---

The Hidden Variable Is Not the Drug, It Is the Tumor’s State

Traditional cancer treatment often behaves like plumbing repair. A problem is found, a tool is selected, and the intervention is applied as quickly and forcefully as possible. Yet the emerging evidence suggests that tumors do not merely differ in location or stage. They differ in state: molecular state, evolutionary state, and treatment-sensitive state.

In metastatic hormone sensitive prostate cancer, the difference between Basal and Luminal B subtypes appears to matter deeply. One molecular subtype may do better with androgen deprivation alone, while another may gain more from adding docetaxel. That is a profound challenge to one-size-fits-all thinking. A therapy that is broadly effective across a population can still be wrong for a biologically distinct subgroup. In fact, it can be not just inefficient but counterproductive.

This is the central lesson of precision oncology: the same tumor type is not the same disease. Two patients with the same organ of origin may live in different therapeutic universes because their cancers are following different internal programs.

Now consider neoadjuvant treatment in localized renal cell carcinoma. The idea here is not to optimize drug choice after disease has already declared itself in the bloodstream. It is to test whether a targeted agent given before surgery can shrink the primary tumor, reduce thrombus burden, or improve operability. Early studies with axitinib suggest measurable tumor reductions, including partial responses in a meaningful fraction of patients. Still, this is not standard care, precisely because the theoretical appeal of preoperative therapy does not automatically translate into a proven advantage.

That tension reveals something important: biology may invite intervention before surgery, but biology does not guarantee benefit from it.

The tumor is not just a mass to remove. It is an evolving system, and treatment is a force that can change the system in ways we do not fully control.

---

The Three Questions That Matter More Than “What Drug?”

The intersection of these stories suggests a better framework for thinking about cancer therapy. Before deciding on any regimen, clinicians and researchers should ask three questions.

1. What is the tumor’s current biology?

This is the molecular question. Is the cancer driven by androgen signaling? Does the subtype suggest vulnerability to chemotherapy or resistance to it? In prostate cancer, subtype can separate patients into different expected benefit groups. That means treatment selection should increasingly reflect the tumor’s internal wiring, not just its anatomical label.

2. What is the treatment trying to accomplish in sequence?

This is the temporal question. Is the goal to extend survival, reduce surgical complexity, preserve future options, or delay progression? The prostate cancer data highlight PFS2, a downstream endpoint that asks not only whether a first treatment helps, but whether it improves what happens after the next treatment. That is a crucial idea. Good therapy is not only about immediate response. It is also about whether the first move leaves the patient in a better position for the second move.

3. What future options does the therapy preserve or foreclose?

This is the evolutionary question. Every intervention reshapes the tumor environment and can alter what works later. A neoadjuvant strategy may shrink a kidney tumor, but it may also change surgical planes, select for resistant clones, or complicate later systemic treatment. A first-line therapy in prostate cancer may improve near-term control but affect sensitivity to later taxane or hormonal therapy.

This is why sequencing is becoming as important as selection. In modern oncology, the order of operations is part of the treatment itself.

---

When “More” Is Not a Synonym for “Better”

Medicine often mistakes intensity for intelligence. If one treatment helps, the reflex is to wonder whether adding another will help more. Sometimes it does. But sometimes escalation is a sign that we have not yet understood the problem deeply enough.

The prostate cancer example illustrates this beautifully. A molecularly broad strategy may appear rational at the population level, yet a specific subtype can experience no benefit, or even relative disadvantage, from the added chemotherapy. That means more treatment is not always better treatment. In some patients, it may simply introduce toxicity without meaningful gain.

The kidney cancer example adds a different kind of restraint. Neoadjuvant therapy sounds attractive because it promises shrinkage before surgery, a kind of preemptive strike. But the clinical status of this approach remains tentative. Why? Because there is a difference between feasibility and value. A tumor can shrink, and yet the patient may not live longer, heal better, or avoid complications. Tumor response is a visible metric, but not necessarily the final one that matters.

This is where oncology becomes philosophically interesting. It forces a confrontation with a hard truth: visible change is not the same as meaningful change.

A 17 percent or 28 percent reduction in tumor size can feel impressive. But if the intervention does not improve surgical outcomes, preserve kidney function, or extend survival, then the shrinkage is only a proxy, not a victory. The same caution applies to prostate cancer. Better progression free survival is meaningful, but only if it maps onto real downstream benefit and aligns with the patient’s biology and priorities.

The deepest challenge, then, is not whether cancer therapy works in an abstract sense. It is whether it works at the right scale of reality: cellular, clinical, and longitudinal.

---

A Better Mental Model: Treat Cancer Like a Chess Game, Not a Hammer Problem

The most useful analogy here is not war, but chess. A hammer treats every problem like a nail. Chess requires reading position, anticipating response, and planning several moves ahead.

In prostate cancer, subtype-guided therapy is a positional strategy. The same opening move does not suit every board. A Basal subtype and a Luminal B subtype may respond differently to the same upfront choice because their internal biology creates different patterns of vulnerability. The idea that one can infer future benefit from the current board state is what makes this more than a simple drug selection problem.

Neoadjuvant RCC therapy, meanwhile, is like making a preparatory move before a major exchange. Sometimes that move simplifies the board. Sometimes it merely reveals the opponent’s next strategy. Either way, the point is not just to hit the tumor harder. The point is to alter the geometry of the problem.

That phrase matters: alter the geometry.

Cancer therapy is increasingly about changing what is possible next. A therapy can:

• reduce tumor bulk before surgery,
• expose biological sensitivity or resistance,
• buy time before more aggressive systemic treatment,
• or improve the value of future lines by delaying progression.

But every one of those gains must be weighed against the possibility that we are selecting for a tougher adversary, wasting precious treatment opportunities, or overtreating a tumor that might have been managed more simply.

The best treatment is not always the strongest one. It is the one that changes the future most favorably.

That principle unites molecular stratification in prostate cancer with preoperative experimentation in kidney cancer. Both are attempts to make therapy more situated: responsive to context rather than dictated by habit.

---

The New Oncology Question Is About Sequence, Not Just Sensitivity

For years, oncology’s main question was whether a tumor was sensitive to a given agent. That remains important, but it is no longer enough. The more advanced question is about sequence sensitivity: how the response to one treatment shapes the effectiveness of the next.

The prostate cancer finding that PFS2 favored ADT plus apalutamide over ADT plus placebo regardless of the next therapy hints at this broader logic. It suggests that initial treatment does not merely suppress disease temporarily. It may condition the course of subsequent therapy in a favorable way.

This is a subtle but powerful shift. It means the success of a therapy cannot be measured solely by immediate shrinkage or time to progression. A strong first move may improve the entire downstream trajectory. Conversely, a flashy initial response may be a trap if it makes the later game worse.

Neoadjuvant RCC treatment raises the same issue from the opposite direction. If therapy is given before surgery, then the question is not only whether the tumor shrinks. It is whether the shrinkage improves the next essential step, which is often surgery itself. Can the surgeon operate more safely? Can margins improve? Can high-risk anatomy be made more manageable? These are sequence questions, not merely response questions.

This is one reason oncology increasingly resembles systems engineering. You are not just choosing components. You are choosing interactions.

---

What Patients and Clinicians Should Ask Next

The practical implication of this synthesis is simple but demanding: every treatment plan should be judged by how well it integrates biology, timing, and downstream flexibility.

For prostate cancer, this means asking whether molecular subtype should influence the choice between chemotherapy and androgen receptor targeted therapy. Not as an academic curiosity, but as a real decision rule. If Basal subtype behaves differently than Luminal B, then the old habit of treating all metastatic hormone sensitive disease as if it were biologically identical should be retired.

For localized RCC, it means treating neoadjuvant therapy as a hypothesis to be tested, not a default reflex. The fact that axitinib can shrink tumors does not automatically mean every patient should get it before surgery. It means the field should identify which patients might benefit, what outcome should define success, and how to avoid mistaking a radiographic response for a true clinical advance.

For both diseases, the same discipline applies: do not confuse measurable change with durable value.

That discipline is useful beyond oncology. It is a reminder that interventions should be judged not only by whether they work in isolation, but by whether they improve the structure of the entire path ahead.

---

Key Takeaways

1. Ask what state the tumor is in, not just where it is. Molecular subtype can change which treatment is most appropriate.
2. Think in sequences, not isolated moves. A good first treatment should improve the value of the next one, not just the current one.
3. Do not equate shrinkage with success. Tumor reduction is useful only if it leads to better surgery, better survival, or better future options.
4. Use escalation selectively. More treatment can mean more toxicity without more benefit, especially when biology suggests limited sensitivity.
5. Treat cancer as an evolving system. The best therapy changes the trajectory of the disease, not merely its present size.

---

The Real Lesson: Cancer Care Is Becoming a Question of Design

The old image of cancer treatment was linear: diagnose, choose, attack, repeat. The emerging reality is more like design. You are designing a trajectory through a complex biological landscape, where each move changes the terrain.

That is why these two seemingly distant stories belong together. Prostate cancer subtype selection shows that the same treatment can have different meaning depending on tumor biology. Neoadjuvant kidney cancer treatment shows that timing can be just as important as the agent itself. Together they argue for a more mature oncology, one that is less impressed by maximal force and more attentive to fit.

In that sense, the future of cancer therapy may not belong to the biggest hammer. It may belong to the best map.

And once you see treatment as mapping rather than smashing, a new question emerges: not “How much should we do?” but “What move best preserves the patient’s future?” That is a harder question. It is also the one medicine increasingly has to answer.